House committee launches investigation into Eli Lilly's China clinical trials at military hospitals and Xinjiang facilities, citing biotech risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results